PL3823623T3 - Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu - Google Patents
Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemuInfo
- Publication number
- PL3823623T3 PL3823623T3 PL19768898.9T PL19768898T PL3823623T3 PL 3823623 T3 PL3823623 T3 PL 3823623T3 PL 19768898 T PL19768898 T PL 19768898T PL 3823623 T3 PL3823623 T3 PL 3823623T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- multiple sclerosis
- preventing multiple
- aminopyrimidine compound
- substituted aminopyrimidine
- Prior art date
Links
- -1 AMINOPYRIMIDINE COMPOUND Chemical class 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700977P | 2018-07-20 | 2018-07-20 | |
| US201862730184P | 2018-09-12 | 2018-09-12 | |
| US201962839273P | 2019-04-26 | 2019-04-26 | |
| PCT/IB2019/056198 WO2020016850A1 (en) | 2018-07-20 | 2019-07-19 | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3823623T3 true PL3823623T3 (pl) | 2025-03-24 |
Family
ID=67953828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19768898.9T PL3823623T3 (pl) | 2018-07-20 | 2019-07-19 | Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12251382B2 (pl) |
| EP (1) | EP3823623B1 (pl) |
| JP (1) | JP7724151B2 (pl) |
| KR (1) | KR20210034623A (pl) |
| CN (1) | CN112437665A (pl) |
| AU (2) | AU2019306828A1 (pl) |
| BR (1) | BR112021000893A2 (pl) |
| CA (1) | CA3106772A1 (pl) |
| DK (1) | DK3823623T3 (pl) |
| ES (1) | ES3009670T3 (pl) |
| FI (1) | FI3823623T3 (pl) |
| HR (1) | HRP20241737T1 (pl) |
| HU (1) | HUE069840T2 (pl) |
| IL (1) | IL280197A (pl) |
| MX (1) | MX2021000094A (pl) |
| PL (1) | PL3823623T3 (pl) |
| PT (1) | PT3823623T (pl) |
| SG (1) | SG11202100518TA (pl) |
| TW (1) | TWI879737B (pl) |
| UA (1) | UA127744C2 (pl) |
| WO (1) | WO2020016850A1 (pl) |
| ZA (1) | ZA202101118B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010513A (es) * | 2020-02-28 | 2022-09-21 | Genentech Inc | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |
| IL308011A (en) | 2021-05-14 | 2023-12-01 | Loxo Oncology Inc | COCRYSTALLINE FORMS OF BRUTON'S TYROSINE KINASE INHIBITOR |
| US20240327379A1 (en) * | 2021-07-15 | 2024-10-03 | Sandoz Ag | Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one |
| EP4543452A1 (en) | 2022-06-24 | 2025-04-30 | Merck Patent GmbH | Treatment regimen for autoimmune diseases and inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10060388A1 (de) * | 2000-12-05 | 2002-06-06 | Merck Patent Gmbh | Verwendung von Pyrazolo [4,3-d]pyrimidinen |
| WO2011156900A2 (en) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Compounds, compositions and methods for treatment of multiple sclerosis |
| LT2718270T (lt) * | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| AU2013207972B2 (en) * | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
| EP3377484B1 (en) * | 2015-11-17 | 2023-09-06 | Merck Patent GmbH | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
| US10464923B2 (en) * | 2017-02-27 | 2019-11-05 | Merck Patent Gmbh | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
-
2019
- 2019-07-19 FI FIEP19768898.9T patent/FI3823623T3/fi active
- 2019-07-19 CN CN201980048404.9A patent/CN112437665A/zh active Pending
- 2019-07-19 WO PCT/IB2019/056198 patent/WO2020016850A1/en not_active Ceased
- 2019-07-19 HR HRP20241737TT patent/HRP20241737T1/hr unknown
- 2019-07-19 TW TW108125526A patent/TWI879737B/zh active
- 2019-07-19 PL PL19768898.9T patent/PL3823623T3/pl unknown
- 2019-07-19 CA CA3106772A patent/CA3106772A1/en active Pending
- 2019-07-19 UA UAA202100604A patent/UA127744C2/uk unknown
- 2019-07-19 MX MX2021000094A patent/MX2021000094A/es unknown
- 2019-07-19 EP EP19768898.9A patent/EP3823623B1/en active Active
- 2019-07-19 DK DK19768898.9T patent/DK3823623T3/da active
- 2019-07-19 ES ES19768898T patent/ES3009670T3/es active Active
- 2019-07-19 PT PT197688989T patent/PT3823623T/pt unknown
- 2019-07-19 JP JP2021503059A patent/JP7724151B2/ja active Active
- 2019-07-19 SG SG11202100518TA patent/SG11202100518TA/en unknown
- 2019-07-19 KR KR1020217004655A patent/KR20210034623A/ko active Pending
- 2019-07-19 AU AU2019306828A patent/AU2019306828A1/en not_active Abandoned
- 2019-07-19 US US17/261,407 patent/US12251382B2/en active Active
- 2019-07-19 HU HUE19768898A patent/HUE069840T2/hu unknown
- 2019-07-19 BR BR112021000893-4A patent/BR112021000893A2/pt unknown
-
2021
- 2021-01-14 IL IL280197A patent/IL280197A/en unknown
- 2021-02-18 ZA ZA2021/01118A patent/ZA202101118B/en unknown
-
2025
- 2025-05-05 AU AU2025203171A patent/AU2025203171A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3823623T3 (da) | 2025-01-02 |
| BR112021000893A2 (pt) | 2021-04-13 |
| JP7724151B2 (ja) | 2025-08-15 |
| TW202019425A (zh) | 2020-06-01 |
| JP2021532104A (ja) | 2021-11-25 |
| HRP20241737T1 (hr) | 2025-02-28 |
| AU2025203171A1 (en) | 2025-05-22 |
| SG11202100518TA (en) | 2021-02-25 |
| EP3823623A1 (en) | 2021-05-26 |
| EP3823623B1 (en) | 2024-10-09 |
| CN112437665A (zh) | 2021-03-02 |
| MX2021000094A (es) | 2021-03-25 |
| HUE069840T2 (hu) | 2025-04-28 |
| US20210260060A1 (en) | 2021-08-26 |
| TWI879737B (zh) | 2025-04-11 |
| AU2019306828A1 (en) | 2021-03-11 |
| KR20210034623A (ko) | 2021-03-30 |
| CA3106772A1 (en) | 2020-01-23 |
| ZA202101118B (en) | 2025-06-25 |
| WO2020016850A1 (en) | 2020-01-23 |
| FI3823623T3 (fi) | 2025-01-09 |
| UA127744C2 (uk) | 2023-12-20 |
| PT3823623T (pt) | 2025-01-06 |
| US12251382B2 (en) | 2025-03-18 |
| IL280197A (en) | 2021-03-01 |
| ES3009670T3 (en) | 2025-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| IL287223B1 (en) | kras g12c inhibitors and methods of using them | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| PL3661954T3 (pl) | Muteiny interleukiny 21 i sposoby leczenia | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL286248B2 (en) | Tyk2 inhibitors and uses thereof | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| PL3777419T3 (pl) | System i sposób zapewniania alokacji w dziedzinie czasu w systemie komunikacyjnym | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| PL3484469T3 (pl) | Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych | |
| PL3464368T3 (pl) | Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka | |
| IL280761A (en) | Devices and systems for body cavities and methods of use | |
| MX2019006950A (es) | Metodos para tratar la sinaptopatia coclear. | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| PL3823623T3 (pl) | Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu | |
| EP4017924A4 (en) | SURFACE TREATMENT COMPOSITIONS AND METHODS | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| PL3478719T3 (pl) | Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kości | |
| IL271464A (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
| IT201700085412A1 (it) | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |